Aurobindo Pharma quarterly results and financials

Aurobindo Pharma (AUROPHARMA)₹1,855+2.84%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Jun 2026 quarter (consolidated), Aurobindo Pharma reported sales of ₹9,164 Cr, up 16.4% from Jun 2025, and net profit of ₹1,028 Cr, up 25.2% year on year. For the year to Mar 2026, sales were ₹33,715 Cr and net profit ₹3,490 Cr.

Sales (Jun 2026): ₹9,164 Cr
Net profit (Jun 2026): ₹1,028 Cr
Sales (FY Mar 2026): ₹33,715 Cr
Net profit (FY Mar 2026): ₹3,490 Cr
EPS (Jun 2026): ₹17.79
Borrowings (Mar 2026): ₹8,054 Cr

Company filings, consolidated accounts; latest reported quarter Jun 2026

Aurobindo Pharma quarterly results

₹ crore unless stated; each column is a quarter.

Aurobindo Pharma Quarterly results
	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	7,227	7,360	7,588	7,580	7,803	7,988	8,395	7,875	8,291	8,651	8,869	9,164
Expenses	5,852	5,755	5,923	5,949	6,233	6,409	6,630	6,267	6,607	6,879	7,109	7,274
Operating Profit	1,375	1,603	1,663	1,621	1,570	1,581	1,764	1,606	1,681	1,776	1,752	1,885
OPM %	19.0%	22.0%	22.0%	21.0%	20.0%	20.0%	21.0%	20.0%	20.0%	21.0%	20.0%	21.0%
Other Income	188	163	14.02	221	136	159	135	107	122	123	117	224
Interest	68.28	76.24	89.33	111	113	119	115	98.39	95.36	93.37	98.42	102
Depreciation	419	424	355	405	384	420	446	408	431	467	481	489
Profit before tax	1,073	1,258	1,228	1,320	1,204	1,197	1,333	1,203	1,273	1,336	1,288	1,510
Tax %	30.0%	26.1%	26.0%	31.0%	32.0%	30.1%	32.1%	32.1%	34.0%	32.0%	29.0%	32.0%
Exceptional items	0.00	0.00	−65.20	0.00	0.00	0.00	0.00	0.00	0.00	−44.08	0.00	−24.04
Net Profit	750	938	904	915	815	844	900	821	846	908	918	1,028
EPS (Rs)	12.91	15.97	15.52	15.70	14.06	14.57	15.55	14.19	14.60	15.66	15.87	17.79

Aurobindo Pharma profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Aurobindo Pharma Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	13,780	14,926	16,495	19,594	23,142	24,817	23,469	24,893	29,032	31,772	33,715	34,975
Expenses	10,586	11,481	12,700	15,628	18,268	19,517	19,060	21,173	23,188	25,195	26,804	27,868
Operating Profit	3,199	3,449	3,779	3,961	4,855	5,293	4,406	3,716	5,836	6,574	6,879	7,095
OPM %	23.1%	23.1%	23.1%	20.0%	21.0%	21.0%	19.0%	15.0%	20.0%	21.0%	20.0%	20.3%
Other Income	200	115	105	70.08	166	3,196	152	291	367	614	404	587
Interest	258	67.28	78.32	264	306	74.26	49.15	140	291	459	386	389
Depreciation	393	430	560	671	970	1,059	1,130	1,249	1,527	1,655	1,785	1,867
Profit before tax	2,736	3,053	3,235	3,083	3,734	7,330	3,362	2,606	4,372	5,057	5,102	5,407
Tax %	26.0%	25.1%	25.1%	24.0%	24.1%	27.0%	22.0%	26.0%	28.0%	31.1%	31.0%	—
Exceptional items	−4.01	−5.01	0.00	−66.16	−20.06	1,929	−109	8.03	−100	33.07	−58.13	−68.12
Net Profit	2,019	2,295	2,415	2,359	2,837	5,316	2,641	1,923	3,158	3,471	3,490	3,699
EPS (Rs)	34.62	39.28	41.37	40.32	48.59	91.00	45.16	32.87	54.17	59.96	60.37	63.92
Dividend payout %	7.0%	6.1%	6.0%	6.0%	6.0%	4.0%	20.1%	23.1%	8.0%	0.0%	7.1%	—

Aurobindo Pharma balance sheet

₹ crore, at each year end.

Aurobindo Pharma Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	28.94	58.87	58.83	58.91	58.84	58.80	58.80	58.86	58.89	58.81	57.86	57.82
Reserves	5,120	7,215	9,294	11,599	13,818	16,747	21,845	24,482	26,727	29,712	32,528	37,792
Borrowings	4,436	5,027	3,354	4,758	6,942	5,806	5,321	2,843	5,268	6,630	8,242	8,054
Other Liabilities	3,307	3,576	3,470	4,514	5,420	6,119	6,164	6,209	7,414	8,266	8,607	12,250
Total Liabilities	12,892	15,875	16,177	20,929	26,238	28,731	33,388	33,592	39,468	44,666	49,434	58,153
Fixed Assets	3,710	4,187	4,839	6,532	8,486	9,411	9,385	10,546	11,038	14,528	14,828	17,440
CWIP	418	846	1,454	1,579	1,662	1,981	3,050	3,738	5,375	3,854	4,886	5,194
Investments	20.05	123	247	313	361	556	592	1,000	544	373	253	1,054
Other Assets	8,745	10,719	9,637	12,506	15,729	16,783	20,362	18,309	22,511	25,910	29,468	34,466
Inventories	3,608	4,058	4,331	5,862	7,246	7,703	9,034	7,562	8,513	9,815	10,545	12,058
Trade receivables	3,526	4,585	2,756	3,066	3,402	4,297	3,491	3,993	4,447	4,795	5,721	7,065
Cash & equivalents	470	801	514	1,263	1,959	2,845	5,480	4,191	6,087	6,280	8,246	9,869
Total Assets	12,892	15,875	16,177	20,929	26,238	28,731	33,388	33,592	39,468	44,666	49,434	58,153

Aurobindo Pharma cash flow

₹ crore, for each year.

Aurobindo Pharma Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	1,238	1,421	3,283	1,955	1,652	4,388	3,332	5,022	2,390	2,438	3,928	5,530
Cash from investing activity	−1,019	−1,446	−1,788	−1,930	−2,909	−1,564	597	−3,214	−3,973	−4,245	−1,867	−2,634
Cash from financing activity	92.95	365	−1,915	864	1,917	−1,946	−1,365	−2,969	1,813	799	120	−1,269
Net cash flow	313	340	−424	892	665	870	2,561	−1,163	230	−1,007	2,177	1,628
Capex	768	1,564	1,694	1,529	1,559	1,430	1,875	2,705	2,719	3,560	2,519	3,105
Free cash flow	491	−146	1,592	713	114	2,964	1,500	2,689	−322	−1,066	1,406	2,466
CFO / OP %	67.0%	67.1%	118.0%	70.1%	61.1%	106.0%	87.0%	143.1%	84.0%	72.1%	86.0%	107.1%

Aurobindo Pharma ratios

Working-capital days and returns, by year.

Aurobindo Pharma Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	107	122	68	68	64	68	52	62	66	61	66	77
Inventory days	238	239	245	316	303	288	332	271	274	283	294	325
Days payable	136	146	122	128	107	97	103	97	125	129	117	151
Cash conversion cycle	211	218	192	258	261	261	283	238	217	217	245	253
Working capital days	50	44	51	50	25	35	52	84	55	66	49	44
ROCE %	27.1%	27.0%	25.0%	23.0%	18.0%	19.0%	18.0%	13.0%	9.0%	14.0%	14.0%	13.0%

Aurobindo Pharma: frequently asked questions

What are the latest quarterly results of Aurobindo Pharma?

For the Jun 2026 quarter, Aurobindo Pharma reported sales of ₹9,164 Cr, up 16.4% year on year and net profit of ₹1,028 Cr, up 25.2% year on year. The operating margin was 21.0%.

What is the annual revenue of Aurobindo Pharma?

Aurobindo Pharma's sales for the year to Mar 2026 were ₹33,715 Cr; over the last twelve months they were ₹34,975 Cr.

What is the net profit of Aurobindo Pharma?

Net profit for the year to Mar 2026 was ₹3,490 Cr, and ₹3,699 Cr over the last twelve months. Earnings per share over the same trailing period were ₹63.92.

How much debt does Aurobindo Pharma have?

Aurobindo Pharma reported borrowings of ₹8,054 Cr at Mar 2026, against cash and equivalents of ₹9,869 Cr.

What is the free cash flow of Aurobindo Pharma?

Cash from operations was ₹5,530 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹2,466 Cr.

Loading…